Keyword Analysis & Research: chimeric antigen receptor t cell therapy

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
chimeric antigen receptor t cell therapy	0.32	0.1	2177	27	40
chimeric	0.03	0.3	6360	100	8
antigen	1.41	0.3	9924	74	7
receptor	1.57	0.6	611	79	8
t	0.14	0.3	4694	89	1
cell	0.25	0.4	8599	87	4
therapy	1.9	0.5	6091	56	7

Keyword	CPC	PCC	Volume	Score
chimeric antigen receptor t-cell therapy	1.89	1	1999	66
chimeric antigen receptor car t cell therapy	0.45	0.6	3800	36
chimeric antigen receptor t cell car t	1.82	0.3	3226	40
chimeric antigen receptor modified t cells	1.95	0.5	7450	33
chimeric antigen receptor-t cell	1.55	0.6	5828	55
chimeric antigen receptor t	1.54	0.6	3678	70
chimeric antigen t cell	1.42	0.6	8214	17
chimeric antigen receptor therapy	1.48	0.7	506	13
chimeric antigen receptor car t cell	0.76	0.1	8108	36
chimeric t cell therapy	0.63	0.6	3111	53
car chimeric antigen receptor t-cell therapy	1.29	0.2	9915	48
chimeric antigen receptor therapy for cancer	1.61	0.2	1808	19
chimeric autoantibody receptor t cells	0.5	1	6764	27
chimeric antigen receptor t car-t	0.31	0.7	5429	48
chimeric antigen receptor car t-cell therapy	0.58	1	2099	33
chimeric antigen receptor t-cell	1.05	0.7	9153	50
chimeric antigen receptor car t-cell	0.67	0.6	729	86

Chimeric Antigen Receptor T-Cell Therapy - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK537294/

WEBOct 3, 2022 · Chimeric antigen receptors (CARs) are recombinant receptors for antigens which redirect the specificity and function of T lymphocytes and/or other immune cells in a single molecule. The concept of using CARs in cancer immunotherapy is that CARs, which are programmed targeting tumor-associated antigens, can be replicated rapidly and …

DA: 96 PA: 33 MOZ Rank: 49

Chimeric antigen receptor T-cell therapy - Nature
nature.com

https://www.nature.com/articles/nrclinonc.2017.148

WEBSep 19, 2017 · Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment of refractory malignancies, but is associated with unique acute toxicities that need...

DA: 76 PA: 45 MOZ Rank: 94

An introduction to chimeric antigen receptor (CAR) T-cell ... - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/30680780/

WEBAbstract. Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.

DA: 40 PA: 8 MOZ Rank: 62

Chimeric Antigen Receptor (CAR) T-Cell Therapy
lls.org

https://www.lls.org/treatment/types-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy

WEBTocilizumab (Actemra®) is approved for the treatment of adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS).

DA: 55 PA: 42 MOZ Rank: 52

CAR T cell - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/CAR_T_cell

WEBThe receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor. CAR T cell therapy uses T cells engineered with CARs to treat cancer. T cells are modified to recognize cancer cells and destroy them.

DA: 57 PA: 35 MOZ Rank: 33

CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI
cancer.gov

https://www.cancer.gov/about-cancer/treatment/research/car-t-cells

WEBThey are made by collecting T cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of cancer cells.

DA: 90 PA: 72 MOZ Rank: 12

Chimeric Antigen Receptor-T Cell Therapy - PMC - National …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745952/

WEBFeb 2, 2018 · Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies that involves ex vivo genetic modification of T cells to incorporate an engineered CAR. After infusion into the patient, the CAR-expressing T cells recognize specific tumor targets and induce an immune response against them.

DA: 32 PA: 84 MOZ Rank: 73

Chimeric antigen receptor T cell therapy comes to clinical practice
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193999/

WEBApr 1, 2020 · Chimeric antigen receptor T cell ( car - t) therapy, first conceptualized at the end of the 1980s, predicted that the body’s own immune cells could be repurposed to target cancer cells—if the correct target could be identified, and if the T cells would be stimulated on contact to mobilize effector, expansion, and survival mechanisms.

DA: 43 PA: 83 MOZ Rank: 49

Chimeric Antigen Receptors for T cell Immunotherapy: Current
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697438/

WEBThe genetic engineering of T cells through the introduction of a chimeric antigen receptor (CAR) allows for generation of tumor targeted T cells. Once expressed by T cells, CARs combine antigen-specificity with T cell activation in a single fusion molecule.

DA: 51 PA: 14 MOZ Rank: 33

What is chimeric antigen receptor-T cell therapy?
mayoclinic.org

https://cancerblog.mayoclinic.org/2022/04/21/what-is-chimeric-antigen-receptor-t-cell-therapy/

WEBApr 21, 2022 · Mayo Clinic Minute: What is chimeric antigen receptor-T cell therapy. From an accredited US hospital. CAR-T cell therapy is a personalized treatment giving hope to patients diagnosed with various lymphomas. "Lymphoma in plain terms is essentially a cancer of your immune system," says Dr. Madiha Iqbal, a Mayo Clinic hematologist and oncologist.

DA: 41 PA: 39 MOZ Rank: 80